Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etravirine Once Daily in Treatment-Naïve HIV-1
NCT00959894Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Sep 2009
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etravirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Percentage of Participants With HIV RNA < 50 Copies/mL at 24 weeks. Started Sep 2009; status: completed.
02
Drugs
etravirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00959894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00959894.